Safety and Efficacy of the Vascular Closure Device (Tonbridge) in Hemostasis Treatment of Femoral Artery Puncture

Inclusion Criteria: Age 18-80, male or non-pregnant female; Subjects undergoing unilateral femoral artery retrograde puncture for angiography or interventional procedure; Using guide sheath ≥5F to ≤8F, and length ≤12cm in angiography or interventional procedure; Subjects or their legal guardians voluntarily participate in this study, can complete follow-ups, and sign the informed consent form. Exclusion Criteria: Ipsilateral common femoral artery occlusion or lumen diameter < 5mm; Inability to walk; Allergy to contrast media; Allergy to PGA or PEG; subjects with a history of common femoral artery surgery, percutaneous transluminal angioplasty (PTA), stent implantation, or vascular graft; Subjects with bleeding tendency, such as thrombocytopenia (platelet count <100×109/L), hemophilia, von willebrand diseases, pre-procedure INR >1.5, etc.; Subjects have taken anticoagulants for a long term before the procedure and have blood coagulation disorders; BMI >40kg/m^2; Subjects receive thrombolytic therapy (such as streptokinase, urokinase, t-PA) within≤24 hours before vascular closure; Local infections or skin infections of the investigational limb; Subjects with target femoral artery dissection or aneurysm within 30 days before intervention procedure; Subjects with puncture site have been punctured through the posterior wall of the femoral artery, or have been punctured several times (≥3 times), or have bleeding or hematoma on the femoral artery puncture site during the procedure; Subjects with clinically significant peripheral vascular diseases (such as severe calcification, arteritis, stenosis, etc) near the puncture site; Women who are pregnant or breastfeeding, OR men or women who plan to have a child in the next 6 months; Subjects who are enrolled in other clinical trials and don't complete; Subjects are considered not suitable for enrollment by the investigators.